New pill takes on hard-to-treat blood cancers in first human trial
Disease control
Recruiting now
This early-phase study tests an experimental oral drug, GLB-001, in about 48 adults with acute myeloid leukemia or high-risk myelodysplastic syndromes that returned or didn't respond to prior therapy. The main goals are to find a safe dose and check for side effects. Researchers …
Phase: PHASE1 • Sponsor: GluBio Therapeutics Inc. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC